Izotropic Corporation has announced promising scientific research results related to its IzoView Breast CT Imaging System. The findings highlight IzoView's potential to revolutionize breast cancer imaging by offering true 3D imaging without the need for breast compression, effectively bridging the gap between digital breast tomosynthesis (DBT) and magnetic resonance imaging $(MRI.AU)$. IzoView is designed to integrate seamlessly into various healthcare environments and aims to provide a more accurate and patient-friendly alternative to existing imaging technologies. These results will be presented in future scientific forums, as the company continues to demonstrate IzoView's capabilities and clinical advantages.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.